Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, June 3, 2021 1:00 - 5:00 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Tim Langford, PharmD, BCPS, USPHS; Robin Moody, MPH; Caryn Mickelson, PharmD, Cathy Zehrung, PharmD

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW; Kyle Hamilton.

Audience: Andrea Willcuts, Takeda; Andrew Yu, Novartis; Bill McDougall, Biogen; Brandie Feger, Advanced Health; Brandon Yip, Sanofi-Genzyme; Carrie Johnson, PharmD, Amgen; Chi Kohlhoff, Viela Bio; Chris Yates, Merck; Craig Sexton, GSK; Cyreatha Bryant, RPh, Gainwell Technologies; Dennis Schaffner, Sanofi-Genzyme; Gregg Rasmussen, Vertex Pharmaceuticals; Jason Tessmer, Novo Nordisk; Jennifer Shear, PharmD, Teva; Joel Rios, Gainwell Technologies; Kalpesh Patel, Gainwell Technologies; Kara Tyler, Kite Pharma; Katie Scheelar, Moda/EOCCO; Lindsey Walter, Novartis; Lisa Allen, Vertex Pharmaceuticals; Lisa Dunn, Amgen; Lynda Finch, PhD, Biogen; Margaret Olmon, PharmD, AbbVie; Mark Kantor, AllCare CCO; Matt Worthy, OHSU; Timothy McFerrin, Alkermes; Melissa Snider, Gilead Sciences; Michael Foster, BMS; Mike Donabedian, Sarepta Therapeutics; Nancy Mahler, Oncopeptides; Rebecca Rubin, BioCryst; Rick Frees, Vertex; Robert Pearce, Teva; Shirley Quach, Novartis; Sophia Yun, Janssen; Steve Hall, Genentech; Tina Shriner, AbbVie; Wendy Bibeau, BMS.

(*) Provided verbal testimony
Written testimony: Posted to OSU Website
I. CALL TO ORDER

A. Roll Call & Introductions
   a. Called to order at approx. 1:08 p.m., introductions by staff and committee.

B. Approval of Agenda

C. Conflict of Interest Declaration

D. Approval of April 2021 Minutes presented by Mr. Citron
   ACTION: Motion to approve, 2nd, all in favor

E. Department Update

F. Legislative Update

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Reports

B. Colony Stimulating Factors Literature Scan

C. Oncology Prior Authorization Updates

D. Orphan Drug Policy Updates
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Rich Holsapple, RPh

B. RetroDUR Report: Dave Engen, PharmD

C. Oregon State Drug Review: Kathy Sentena, PharmD
   a. Covid-19 Viral Testing
   b. 2019-2020 Food and Drug Administration Drug Safety Communications Update
   c. Coronavirus Disease-2019 Vaccine Update

IV. DUR OLD BUSINESS

A. Antipsychotics in Young Children Safety Edit: Sarah Servid, PharmD
   Recommendations:
   a. Implement a safety edit to ensure appropriate use of antipsychotics in children 5 years of age or less
   b. Implement a retrospective provider outreach program
   ACTION: Motion to approve, 2nd, all in favor
V. PREFERRED DRUG LIST NEW BUSINESS

A. Growth Hormone ADR & Prior Authorization (PA) Update: Dave Engen, PharmD
   Recommendation:
   a. Add somapacitan-beco to Growth Hormone PDL class, designate non-preferred, and restrict use for OHP-covered conditions
   b. Update to PA criteria to align with HERC coverage guidance and FDA-approved indications
   ACTION: Motion to approve, 2nd, all in favor

B. Hereditary Angioedema Class Update (NDE): Sarah Servid, PharmD
   Recommendation:
   a. Update PA criteria to include berotralstat
   b. No changes to the PDL based on clinical evidence
   c. Evaluate costs in executive session
   ACTION: Motion to approve, 2nd, all in favor

C. Multiple Sclerosis Drug Class Update & New Drug Evaluation for Kesimpta (Ofatumumab) and Ponvory (Ponesimod) (NDE): Deanna Moretz, PharmD
   Recommendations:
   a. Update PA criteria to apply to ofatumumab for both PAD and POS pharmacy claims
   b. Add ponesimod tablets to the Oral MS Drug PA criteria and update as proposed
   c. Evaluate costs in executive session
   Public Comment: Wendy Bibeau, BMS; Lynda Finch, Biogen; Steve Hall, Genentech; Shirley Quach, Novartis
   ACTION: Motion to approve, 2nd, all in favor

D. Focused Heart Failure Update and New Drug Evaluation for Entresto (Sacubitril/Valsartan) and Verquvo (Vericiguat) (NDE): Megan Herink, PharmD
   Recommendations:
   a. Rename the “ACEIs, ARBs and DRIs” PDL class to “Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS)” and include sacubitril/valsartan
   b. Update PA criteria for sacubitril/valsartan to include expanded FDA indications
   c. Require PA for vericiguat to ensure appropriate use in patients on goal directed therapy with advanced symptomatic HFrEF
   d. Evaluate costs in executive session
   Public Comment: Shirley Quach, Novartis
   ACTION: Motion to approve, 2nd, all in favor

E. Platelet Inhibitor Class Update: Kathy Sentena, PharmD
   Recommendations:
   a. Update PA criteria to include new indications for ticagrelor
b. No changes to the PDL based on the evidence identified since the last review  
c. Evaluate costs in executive session  
ACTION: Motion to approve, 2nd, all in favor

VI. DUR NEW BUSINESS

A. **Migraine Prophylaxis Drug Use Evaluation (DUE):** Rebekah Bartholomew, PGY2 Resident; Megan Herink, PharmD; Sara Fletcher, PharmD  
**Recommendation:**  
a. No policy changes for triptan therapy are recommended at this time  
b. Consider provider education to increase migraine prophylaxis use in patients taking chronic triptans  
c. No PA criteria changes for CGRP antagonists recommended at this time  
**Public Comment:** Jennifer Shear, Teva; Carrie Johnson, Amgen; Margaret Olmon, Abbvie  
**ACTION:** Motion to approve, 2nd, all in favor

B. **Prior Authorization Criteria Update, Cystic Fibrosis:** Megan Herink, PharmD  
**Recommendation:**  
a. Remove manual review by medical director consistent with FDA labeling and standard of care from PA criteria for use of LUM/IVA in patients less than 12 years of age  
b. Add a link to FDA labeling in the PA criteria to ensure all approved CFTR mutations are current  
**Public Comment:** Lisa Allen, Vertex  
**ACTION:** Motion to approve, 2nd, all in favor

VII. EXECUTIVE SESSION

**Members Present:** Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Tim Langford, PharmD, BCPS, USPHS; Caryn Mickelson, PharmD; Robin Moody, MPH  
**Staff Present:** Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW
VIII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Colony Stimulating Factors Literature Scan:
   Recommendation: Make Nyvepria preferred and Neulasta non-preferred on the PDL

B. Hereditary Angioedema:
   Recommendation: No changes to the PDL are recommended

C. Multiple Sclerosis Class Update:
   Recommendation: Maintain non-preferred status for Kesimpta and Ponvory on the PDL

D. Focused Heart Failure Class Update:
   Recommendation: Make Entresto non-preferred on the PDL

E. Platelet Inhibitors:
   Recommendation: Make Prasugrel preferred on the PDL and remove from PA criteria

ACTION: Motion to approve, 2nd, all in favor

IX. ADJOURN